A new artificial pancreas system that both doses and takes away insulin is showing critical benefits in helping those with type 1 diabetes maintain more consistent, and healthier, glucose levels.
Two studies, shared this weekend, showed that the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology by Tandem® Diabetes Care resulted in more time in range – less highs, less lows – with no severe hypoglycemic events.
“Fantastic results, showing the potential for another system for the T1D Community in sight,” said JDRF President and CEO Aaron Kowalski, PhD.
The t:slim X2 insulin pump with Control-IQ technology utilizes Dexcom G6 continuous glucose monitoring (CGM) sensor values to predict glucose levels and adjust insulin delivery to prevent highs and lows, while still allowing the user to manually bolus for meals. The system also automates correction boluses, which is a feature not commercially available today on automated insulin delivery devices.
The results of the first large-scale, 6-month closed-loop study, were presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco. Company leaders say they will now share the study results with the FDA, hoping approval would lead to a commercial launch in the second half of 2019.
Critical in determining potential benefits of the technology, the study was funded by the U.S. Special Diabetes Program. JDRF is a leading advocate for the annual renewal of the SDP program, as it supports critical T1D research such as this study.
JDRF also has been an early and long-term funder of research that helped lead to the development of this new technology.
“Combining Tandem’s t:slim X2 pump with Control-IQ technology and the exceptional accuracy of our Dexcom G6 CGM — which requires zero fingersticks for operation — has delivered what promises to be the most advanced, simple-to-use hybrid closed-loop system to date,” said Kevin Sayer, president and CEO of Dexcom. “The impressive data released today, combined with our iCGM classification, will help to accelerate innovation and bring powerful insulin delivery tools to people with diabetes more quickly.”
To learn more, read Tandem’s media release here.